032 Citation: Kumar J, Alam MU, Tanneru K, Gautam S, Norez D, et al. (2020) Influence of Intra-ductal Carcinoma on Clinical Outcomes in Men with Prostate Cancer: Systematic Review and Meta-analysis. Glob J Cancer Ther 6(1): 032-037. DOI: https://dx.doi.org/10.17352/2581-5407.000033 https://dx.doi.org/10.17352/gjct DOI: 2581-5407 ISSN: CLINICAL GROUP Introduction Intraductal carcinoma of prostate (IDC-P) is morphologically described as prostatic adenocarcinoma extending into and proliferating within preexisting prostatic ducts. After initial morphological description by Kovi et al in 1985, many pathological studies have been done to reach a fairly established morphology based diagnostic criteria to classify IDC-P on histopathology of surgical specimen and needle biopsy [1]. The available studies have shown that identification of IDC-P in prostate cancer tissue to be an independent variable in the prediction of pathological stage, tumor volume, Gleason score and treatment failure [2-4]. This has led to the recommendation for mandatory reporting of IDC-P by the College of American Pathology in 2017 [5]. In the PSA screening era, the incidence of IDC-P is approximately 20% [6,7], which is mostly reported in men with high volume, high grade and advanced adenocarcinoma of the prostate. Abstract Purpose: To provide a comprehensive summary of published literature regarding influence of intraductal carcinoma of prostate (IDC-P) on clinical outcomes in men with Prostate Cancer (PC). Methods: We compared the following clinical endpoints in men with PC with or without IDC-P; Castration Resistant Free Survival (CFS) and Overall Survival (OS) for metastatic PC (Group 1), biochemical recurrence rate (BR) and/or cancer specific survival (CSS) in men undergoing radical prostatectomy (Group 2a) or radiotherapy (Group 2b). A meta-analysis was done by fixed effect model using 12 studies reporting Hazard Ratio (HR) and meeting the selection criteria. Results: In Group 1 for men with IDC-P, the pooled HR for CFS and OS were 1.69 (CI, 1.30-2.21) and 2.00 (CI, 1.38-2.91), respectively. In group 2a BR and CSS were higher in men with IDC-P with HR 2.63 (CI, 1.99-3.49) and 2.87 (CI, 1.65-5.01) respectively. Similarly, presence of IDC-P in group 2b demonstrated a HR of 2.04 (CI, 1.10- 3.78) for BR. Conclusions: Men with IDC-P demonstrated poorer clinical outcomes including higher rate of BR following radical prostatectomy, radiation therapy either in primary and salvage settings, shorter time to CFS and poorer OS in men with metastatic disease. Our analysis and review of the literature suggest that IDC-P could be used as a novel prognostic and predictive morphological biomarker to influence clinical management in men with PC including pelvic lymph node dissection, pelvic radiotherapy or genetic testing. Research Article Influence of Intra-ductal Carcinoma on Clinical Outcomes in Men with Prostate Cancer: Systematic Review and Meta-analysis Jatinder Kumar*, Muhammad Umar Alam, Karthik Tanneru, Shiva Gautam, Daniel Norez, Charu Shastri, Joseph Costa, Mark Bandyk, Hariharan Palayapalayam Ganapathi, Shahriar Koochekpour, Sanjeev Shukla and KC Balaji Department of Urology, University of Florida, Jacksonville, USA Received: 08 October, 2020 Accepted: 16 October, 2020 Published: 17 October, 2020 *Corresponding author: Jatinder Kumar, MD, Clinical Postdoctoral Associate, Department of Urology, Uni- versity of Florida, Jacksonville, Florida, USA, Tel: +1 904 699 7488; Email: ORCID: https://orcid.org/0000-0003-0716-959X https://www.peertechz.com